INBX Inhibrx Biosciences, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2007919 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY550.0%
TTM net income YoY-108.3%
TTM EPS YoY-108.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-10,386.5%
Net margin-10,773.5%
FCF margin-9,986.5%
EBITDA margin-10,195.5%
Returns
ROE-197.8%
ROA-85.6%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets94.5%
Debt / equity12.58x
Current ratio3.93x
Interest coverage-11.07x
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $1.30M | $200,000 | $1.80M |
| R&D expense | $113.03M | $203.74M | $191.64M |
| SG&A expense | $23.30M | $127.91M | $29.38M |
| Operating income | -$135.03M | -$331.45M | -$219.22M |
| Interest expense | $12.20M | $13.49M | $31.84M |
| Pretax income | -$140.05M | $1.69B | -$239.72M |
| Income tax | $2,000 | $2,000 | $3,000 |
| Net income | -$140.06M | $1.69B | -$241.36M |
| EBITDA | -$132.54M | -$329.16M | -$218.03M |
| EPS (basic) | -9.04 | 114.01 | -20.48 |
| EPS (diluted) | -9.04 | 112.62 | -20.48 |
| Weighted avg. shares (diluted) | 15.49M | 14.98M | 11.78M |
| Balance sheet | |||
| Cash & equivalents | $124.22M | $152.60M | $277.92M |
| Current assets | $132.83M | $160.40M | $295.36M |
| PP&E, net | $3.73M | $6.20M | $6.42M |
| Total assets | $146.48M | $180.77M | $307.89M |
| Current liabilities | $33.80M | $40.73M | $56.31M |
| Long-term debt | $100.56M | $0 | $206.97M |
| Total debt | $100.56M | $0 | $206.97M |
| Total liabilities | $138.49M | $47.18M | $264.39M |
| Shareholders' equity | $7.99M | $133.58M | $43.50M |
| Net debt | -$23.66M | -$152.60M | -$70.96M |
| Shares outstanding | 14.58M | 14.48M | 47.37M |
| Cash flow statement | |||
| Operating cash flow | -$129.79M | -$194.41M | -$193.31M |
| Capital expenditure | $31,000 | $2.60M | $4.59M |
| Free cash flow | -$129.82M | -$197.01M | -$197.90M |
| Investing cash flow | -$28,000 | -$2.60M | -$4.59M |
| Financing cash flow | $101.45M | $71.68M | $201.96M |
| Depreciation & amortization | $2.48M | $2.29M | $1.19M |
| Stock-based compensation | $11.14M | $58.52M | $24.85M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.